Founded in 2018, Sandhill Therapeutics has harnessed the power of Natural Killer (NK) cells and innate T cell populations to maximize tumor killing and to provide a cost-effective, universal, immediately available, cellular immuno-oncology therapy.
More than 150 combined years of experience in translation, product development, clinical development, manufacturing, and regulatory in the cell/gene therapy space.
Product and clinical experience in both autologous and allogeneic cell/gene therapies
Experience with cGMP and GCP regulatory activities; participated in EMA submission for ATMP product
Network of cell/gene therapy resources ready to develop commercially attractive off-the-shelf cellular immuno-oncology therapeutics